论文部分内容阅读
目的评价双歧四联活菌制剂联合三联疗法根治幽门螺杆菌(HP)的疗效。方法入选幽门螺杆菌感染所致的消化性溃疡患者126例,随机分A、B 2组,A组65例,单用三联疗法组(奥美拉唑+克拉霉素+甲硝唑);B组61例,加双歧四联活菌制剂组(双歧四联活菌片+三联疗法),疗程均为7 d。A组:口服奥美拉唑肠溶胶囊20 mg,每日1次;克拉霉素缓释片0.5 g,每日1次;甲硝唑片0.2 g,每日3次。B组:加服双歧四联活菌片1.5 g,1日3次,服用时与抗菌药物服用至少间隔2 h,其余药物、疗程同A组。分别观察2组幽门螺杆菌根除率及不良反应发生率。结果三联组和加用双歧四联活菌组的幽门螺杆菌根除率分别为67.7%和86.9%,加用双歧四联活菌组幽门螺杆菌阳转阴率明显高于三联疗法组(P<0.05),三联组不良反应发生率为36.9%,加用双歧四联活菌组为8.2%。2组差异有统计学意义(P<0.01)。结论双歧四联活菌片联合三联疗法能提高对幽门螺杆菌的根除率,并减少胃肠道不良反应。
Objective To evaluate the efficacy of bifidobacterium quadrulmus combined with triple therapy in the treatment of Helicobacter pylori (HP). Methods A total of 126 patients with peptic ulcer caused by Helicobacter pylori infection were randomly divided into groups A and B 2, group A (n = 65) and triple therapy group (omeprazole + clarithromycin + metronidazole). B Group 61 cases, plus bifidobacterium live viable preparation group (bifidobacterium tetanus + triple therapy), treatment were 7 d. Group A: oral omeprazole enteric-coated capsules 20 mg once daily; clarithromycin sustained release tablets 0.5 g once daily; metronidazole tablets 0.2 g three times a day. Group B: Add Bifidobacterium quadrivalent 1.5g, 3 times a day, when taking antimicrobial drugs taking at least 2 hours interval, the remaining drugs, treatment with the A group. The eradication rates of Helicobacter pylori and incidence of adverse reactions in the two groups were observed. Results Helicobacter pylori eradication rates were 67.7% and 86.9% in triply combined group and bifidobacterium group, respectively. The positive conversion rate of Helicobacter pylori to bifidobacterium group was significantly higher than that of triple combination group P <0.05). The incidence of adverse reactions in the triad group was 36.9%, while that in the bifidobacterium group was 8.2%. The difference between the two groups was statistically significant (P <0.01). Conclusion Bifidobacterium quadriceps fentin tablets combined with triple therapy can improve the eradication rate of Helicobacter pylori and reduce gastrointestinal adverse reactions.